The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: a UK-wide cohort study involving 618 161 people in primary care
Open accessPublished version of a preprint
Abstract
Objective: To compare rates of performing National Institute for Health and Care Excellence-recommended health checks and prescribing in people with type 2 diabetes (T2D), before and after the first COVID-19 peak in March 2020, and to assess whether trends varied by age, sex, ethnicity and deprivation. Methods: We studied 618 161 people with T2D followed between March and December 2020 from 1744 UK general practices registered with the Clinical Practice Research Datalink. We focused on six health checks: haemoglobin A1c, serum creatinine, cholesterol, urinary albumin excretion, blood pressure and body mass index assessment. Regression models compared observed rates in April 2020 and between March and December 2020 with trend-adjusted expected rates derived from 10-year historical data. Results: In April 2020, in English practices, rates of performing health checks were reduced by 76%–88% when compared with 10-year historical trends, with older people from deprived areas experiencing the greatest reductions. Between May and December 2020, the reduced rates recovered gradually but overall remained 28%–47% lower, with similar findings in other UK nations. Extrapolated to the UK population, there were ~7.4 million fewer care processes undertaken March–December 2020. In England, rates for new medication fell during April with reductions varying from 10% (95% CI: 4% to 16%) for antiplatelet agents to 60% (95% CI: 58% to 62%) for antidiabetic medications. Overall, between March and December 2020, the rate of prescribing new diabetes medications fell by 19% (95% CI: 15% to 22%) and new antihypertensive medication prescribing fell by 22% (95% CI: 18% to 26%), but prescribing of new lipid-lowering or antiplatelet therapy was unchanged. Similar trends were observed across the UK, except for a reduction in new lipid-lowering therapy prescribing in the other UK nations (reduction: 16% (95% CI: 10% to 21%)). Extrapolated to the UK population, between March and December 2020, there were ~31 800 fewer people with T2D prescribed a new type of diabetes medication and ~14 600 fewer prescribed a new type of antihypertensive medication. Conclusions: Over the coming months, healthcare services will need to manage this backlog of testing and prescribing. We recommend effective communications to ensure patient engagement with diabetes services, monitoring and opportunities for prescribing, and when appropriate use of home monitoring, remote consultations and other innovations in care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benchimol, E. I., Smeeth, L., Guttmann, A., Harron, K., Moher, D., Petersen, I., Sørensen, H. T., von Elm, E., Langan, S. M., & RECORD Working Committee (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001885 · Cited by 5,749
Video consultations for covid-19
Greenhalgh, T., Wherton, J., Shaw, S., & Morrison, C. (2020) · BMJ · doi:10.1136/bmj.m998 · Cited by 866
Padmanabhan, S., Carty, L., Cameron, E., Ghosh, R. E., Williams, R., & Strongman, H. (2019) · European Journal of Epidemiology · doi:10.1007/s10654-018-0442-4 · Cited by 208
Phillip, M., Bergenstal, R. M., Close, K. L., Danne, T., Garg, S. K., Heinemann, L., Hirsch, I. B., Kovatchev, B. P., Laffel, L. M., Mohan, V., et al. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0375 · Cited by 135
Khunti, K., Kosiborod, M., & Ray, K. K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13243 · Cited by 104
Research works printed but not linked: 26
- 10.1371/journal.pone.0132883 · DOI
- 10.1186/1472-6963-10-169 · DOI
- 10.1136/bmjdrc-2016-000291 · DOI
- 10.1136/bmjqs-2012-001033 · DOI
- 10.1136/bmj.m3348 · DOI
- Holman, 2020, Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study, Lancet Diabetes Endocrinol, 8, 823, 10.1016/S2213-8587(20)30271-0 · DOI · Paper page
- Barron, 2020, Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study, Lancet Diabetes Endocrinol, 8, 813, 10.1016/S2213-8587(20)30272-2 · DOI · Paper page
- 10.1016/j.pcd.2010.02.003 · DOI
- Carr, 2021, Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK, Lancet Diabetes Endocrinol, 9, 413, 10.1016/S2213-8587(21)00116-9 · DOI
- 10.1371/journal.pone.0251143 · DOI
- 10.2337/dc20-1176 · DOI
- 10.2337/dc20-0954 · DOI
- 10.2337/dc20-1127 · DOI
- Cusinato, 2021, Anxiety, depression, and glycemic control during Covid-19 pandemic in youths with type 1 diabetes, J Pediatr Endocrinol Metab, 10.1515/jpem-2021-0153 · DOI
- 10.1016/j.appet.2020.104853 · DOI · Paper page
- 10.1002/osp4.442 · DOI
- 10.1016/j.pcd.2021.01.003 · DOI
- 10.1007/s12020-021-02739-5 · DOI
- 10.1016/j.diabres.2021.108840 · DOI
- Rastogi, 2020, Improved glycemic control amongst people with long-standing diabetes during COVID-19 lockdown: a prospective, observational, nested cohort study, Int J Diabetes Dev Ctries, 476, 10.1007/s13410-020-00880-x · DOI
- Ruissen, 2021, Increased stress, weight gain and less exercise in relation to glycemic control in people with type 1 and type 2 diabetes during the COVID-19 pandemic, BMJ Open Diabetes Res Care, 9, 10.1136/bmjdrc-2020-002035 · DOI · Paper page
- 10.1016/j.diabres.2020.108285 · DOI
- 10.1530/eje-20-0377 · DOI
- 10.1016/S2468-2667(20)30201-2 · DOI · Paper page
- 10.1016/S2468-2667(20)30288-7 · DOI · Paper page
- Mansfield, 2021, Indirect acute effects of the COVID-19 pandemic on physical and mental health in the UK: a population-based study, Lancet Digit Health, 3, e217, 10.1016/S2589-7500(21)00017-0 · DOI · Paper page
Cited by
Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning
Drucker, D. J. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.016 · Cited by 272
Lehner, C. T., Eberl, M., Donnachie, E., Tanaka, L. F., Schauberger, G., Schederecker, F., Himmler, S., Sundmacher, L., & Klug, S. J. (2024) · Diabetologia · doi:10.1007/s00125-024-06113-8 · Cited by 18
Barrett, A., Debackere, N., Ribeiro, A., Keapoletswe, K., Zingel, R., & Coles, B. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02540-y · Cited by 6
Metadata
- Authors
- Carr, M. J., Wright, A. K., Leelarathna, L., Thabit, H., Milne, N., Kanumilli, N., Ashcroft, D. M., & Rutter, M. K.
- Venue
- BMJ Quality & Safety
- Publisher
- BMJ
- Published
- 2021-10-12
- Volume
- 31
- Issue
- 7
- Pages
- 503-514
- ISSN
- 1475-3898 (ISSN-L)
- 2044-5415
- 2044-5423
- OpenAlex
- W3206592938
- Cited by
- 222
- References
- 5
- FWCI
- 17.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- National Institute for Health Research (NIHR) Greater Manchester Patient Safety Translational Research Centre (PSTRC-2016-003)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: a UK-wide cohort study involving 618 161 people in primary care. https://app.cochat.ai/papers/10.1136/bmjqs-2021-013613
- The paper
- Carr, M. J., Wright, A. K., Leelarathna, L., Thabit, H., Milne, N., Kanumilli, N., Ashcroft, D. M., & Rutter, M. K. (2022). Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: a UK-wide cohort study involving 618 161 people in primary care. BMJ Quality & Safety. https://doi.org/10.1136/bmjqs-2021-013613
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.